Literature DB >> 33580935

Eosinophilic fasciitis induced by natalizumab in a patient affected by multiple sclerosis.

Vincenzo Maione1, Laura Miccio1, Raffaella Sala1, Claudia Zambelli2, Piergiacomo Calzavara-Pinton1.   

Abstract

Entities:  

Year:  2021        PMID： 33580935     DOI： 10.25259/IJDVL_259_19

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN： 0378-6323            Impact factor:   2.545


× No keyword cloud information.
  5 in total

Review 1.  Eosinophilic Skin Diseases: A Comprehensive Review.

Authors:  Hai Long; Guiying Zhang; Ling Wang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

2.  Hypereosinophilia in patients with multiple sclerosis treated with natalizumab.

Authors:  M Abbas; P H Lalive; M Chofflon; H-U Simon; C Chizzolini; C Ribi
Journal:  Neurology       Date:  2011-10-05       Impact factor: 9.910

3.  Eosinophilic fasciitis occurring under treatment with natalizumab for multiple sclerosis.

Authors:  Janie Bujold; Catherine Boivin; Mohamed Amin; Jean-Pierre Bouchard; Jacques Soucy
Journal:  J Cutan Med Surg       Date:  2014 Jan-Feb       Impact factor: 2.092

4.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

5.  Pulmonary eosinophilia associated to treatment with natalizumab.

Authors:  Elena Curto; Elvira Munteis-Olivas; Eva Balcells; M Marisol Domínguez-Álvarez
Journal:  Ann Thorac Med       Date:  2016 Jul-Sep       Impact factor: 2.219
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.